NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

werent we told this was required by the FDA?

More recently that was the supposition but early on when I began investing we were told that without a crossover option it would be hard to recruit sufficient patients and that having the option to at least belatedly get DCVax-L after recurrence if one were in the placebo group was an important inducement not to mention the humane thing to do.

I would not be surprised if a regulator required it but Dr. Liau danced around that point to avoid appearing to blame regulators for issues like confounding.

So both things could be true in that a crossover was necessary to get enough patients and regulators, due to patient interests wanted it to go that way as well.